DSpace university logo mark
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 030 医学部 > 030 学術雑誌論文 >

Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis

ファイル 記述 サイズフォーマット
PLoS12_177057.pdf2.02 MBAdobe PDF本文ファイル

タイトル: Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis
著者: Iwamoto, Naoki / Tsuji, Sosuke / Takatani, Ayuko / Shimizu, Toshimasa / Fukui, Shoichi / Umeda, Masataka / Nishino, Ayako / Horai, Yoshiro / Koga, Tomohiro / Kawashiri, Shin-ya / Aramaki, Toshiyuki / Ichinose, Kunihiro / Hirai, Yasuko / Tamai, Mami / Nakamura, Hideki / Terada, Kaoru / Origuchi, Tomoki / Eguchi, Katsumi / Ueki, Yukitaka / Kawakami, Atsushi
発行日: 2017年 5月 4日
出版者: Public Library of Science
引用: PLOS ONE, 12(5), e0177057; 2017
抄録: Objective We evaluated the efficacy and safety of tofacitinib in patients with rheumatoid arthritis (RA) in a real-world setting. Methods Seventy consecutive patients, for whom tofacitinib was initiated between November 2013 and May 2016, were enrolled. All patients fulfilled the 2010 ACR/EULAR classification criteria for RA. All patients received 5 mg of tofacitinib twice daily and were followed for 24 weeks. Clinical disease activity indicated by disease activity score (DAS)28-ESR, the simplified disease activity index, and the clinical disease activity index as well as adverse events (AEs) were evaluated. Statistical analysis was performed to determine which baseline variables influenced the efficacy of tofacitinib at 24 weeks. Results Fifty-eight patients (82.9%) continued tofacitinib at 24 weeks. Clinical disease activity rapidly and significantly decreased, and this efficacy continued throughout the 24 weeks: i.e., DAS28-ESR decreased from 5.04 ± 1.33 at baseline to 3.83 ± 1.11 at 4 weeks and 3.53 ± 1.17 at 24 weeks (P<0.0001, vs. baseline). 15 AEs including 5 herpes zoster infection occurred during tofacitinib treatment. The efficacy of tofacitinib was not changed in patients without concomitant use of methotrexate (MTX) or patients whose treatment with tocilizumab (TCZ) failed. Multivariable logistic analysis showed that the number of biologic DMARDs (bDMARDs) previously used was independently associated with achievement of DAS-low disease activity. Conclusions Our present study suggests that tofacitinib is effective in real-world settings even without concomitant MTX use or after switching from TCZ. Our results also suggest that its efficacy diminishes if started after use of multiple bDMARDs.
URI: http://hdl.handle.net/10069/37558
DOI: 10.1371/journal.pone.0177057
権利: © 2017 Iwamoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
資料タイプ: Journal Article
原稿種類: publisher
出現コレクション:030 学術雑誌論文

引用URI : http://hdl.handle.net/10069/37558



Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace